Literature DB >> 26194695

ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.

Maik Dahlhoff1, Matthias Schäfer2, Sukalp Muzumdar2, Christian Rose3, Marlon R Schneider4.   

Abstract

The epidermal growth factor receptor (EGFR) plays a key role in skin inflammation, wound healing, and carcinogenesis. Less is known about the functions of the structurally related receptor ERBB3 (HER3) in the skin. We assessed the requirement of ERBB3 for skin homeostasis, wound healing, and tumorigenesis by crossing mice carrying a conditional Erbb3 allele with animals expressing cre under the control of the keratin 5 promoter. Erbb3(del) mice, lacking ERBB3 specifically in keratinocytes, showed no obvious abnormalities. The EGFR was upregulated in Erbb3(del) skin, possibly compensating the loss of ERBB3. Nonetheless, healing of full-thickness excisional wounds was negatively affected by ERBB3 deficiency. To analyze the function of ERBB3 during tumorigenesis, we employed the established DMBA/TPA multi-stage chemical carcinogenesis protocol. Erbb3(del) mice remained free of papillomas for a longer time and had significantly reduced tumor burden compared to control littermates. Tumor cell proliferation was considerably reduced in Erbb3(del) mice, and loss of ERBB3 also impaired keratinocyte proliferation after a single application of TPA. In human skin tumor samples, upregulated ERBB3 expression was observed in squamous cell carcinoma, condyloma, and malignant melanoma. Thus, we conclude that ERBB3, while dispensable for the development and the homeostasis of the epidermis and its appendages, is required for proper wound healing and for the progression of skin tumors during multi-stage chemical carcinogenesis in mice. ERBB3 may also be important for human skin cancer progression. The latter effects most probably reflect a key role for ERBB3 in increasing cell proliferation after stimuli as wounding or carcinogenesis.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; EGFR; ERBB3; Mouse; Skin; Wound healing

Mesh:

Substances:

Year:  2015        PMID: 26194695      PMCID: PMC5528713          DOI: 10.1016/j.molonc.2015.06.007

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  27 in total

1.  Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor.

Authors:  Sofi Forsberg; Ola Rollman
Journal:  J Dermatol Sci       Date:  2010-04-03       Impact factor: 4.563

2.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.

Authors:  Fumin Shi; Shannon E Telesco; Yingting Liu; Ravi Radhakrishnan; Mark A Lemmon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 3.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

4.  Modulation of porcine wound repair with a transfected ErbB3 gene and relevant EGF-like ligands.

Authors:  Martina I Okwueze; Nancy L Cardwell; Alonda C Pollins; Lillian B Nanney
Journal:  J Invest Dermatol       Date:  2006-11-23       Impact factor: 8.551

5.  Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.

Authors:  Michael Piepkorn; Holly Predd; Robert Underwood; Paul Cook
Journal:  Arch Dermatol Res       Date:  2003-05-27       Impact factor: 3.017

6.  NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Authors:  Kristina Buac; Mai Xu; Julie Cronin; Ashani T Weeraratna; Stephen M Hewitt; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-30       Impact factor: 4.693

7.  A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination.

Authors:  Angel Ramirez; Angustias Page; Alberto Gandarillas; Jennifer Zanet; Sophie Pibre; Miguel Vidal; Laura Tusell; Anna Genesca; Duncan A Whitaker; David W Melton; Jose L Jorcano
Journal:  Genesis       Date:  2004-05       Impact factor: 2.487

Review 8.  Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology.

Authors:  Marlon R Schneider; Sabine Werner; Ralf Paus; Eckhard Wolf
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

Review 9.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08

Review 10.  Targeting of erbB3 receptor to overcome resistance in cancer treatment.

Authors:  Jian Ma; Hui Lyu; Jingcao Huang; Bolin Liu
Journal:  Mol Cancer       Date:  2014-05-08       Impact factor: 27.401

View more
  11 in total

1.  The protective effect of betacellulin against acute pancreatitis is ERBB4 dependent.

Authors:  Kathrin Hedegger; Franziska Stumpf; Helmut Blum; Alexander Graf; Roland Michael Schmid; Marina Lesina; Hana Algül; Marlon Roberto Schneider; Maik Dahlhoff
Journal:  J Gastroenterol       Date:  2019-08-27       Impact factor: 7.527

2.  ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.

Authors:  Maik Dahlhoff; Matthias Schäfer; Sukalp Muzumdar; Christian Rose; Marlon R Schneider
Journal:  Mol Oncol       Date:  2015-07-03       Impact factor: 6.603

3.  Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.

Authors:  Russell Moser; Kay E Gurley; Olga Nikolova; Guangrong Qin; Rashmi Joshi; Eduardo Mendez; Ilya Shmulevich; Amanda Ashley; Carla Grandori; Christopher J Kemp
Journal:  Oncogene       Date:  2022-05-10       Impact factor: 8.756

4.  Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway.

Authors:  Deepti Bajpai; Spencer Mehdizadeh; Akihiko Uchiyama; Yuta Inoue; Andrew Sawaya; Andrew Overmiller; Stephen R Brooks; Kowser Hasneen; Meghan Kellett; Elisabetta Palazzo; Sei-Ichiro Motegi; Stuart H Yuspa; Christophe Cataisson; Maria I Morasso
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

5.  Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review.

Authors:  Xiaofeng Li; Yueming He; Jinfeng Zhu; Hongxia Pang; Yongwei Lin; Jinyang Zheng
Journal:  Oncotarget       Date:  2018-09-14

6.  NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.

Authors:  Ganapati V Hegde; Cecile de la Cruz; Jennifer M Giltnane; Lisa Crocker; Avinashnarayan Venkatanarayan; Gabriele Schaefer; Debra Dunlap; Joerg D Hoeck; Robert Piskol; Florian Gnad; Zora Modrusan; Frederic J de Sauvage; Christian W Siebel; Erica L Jackson
Journal:  Elife       Date:  2019-05-30       Impact factor: 8.140

7.  Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.

Authors:  Mary B Kelley; Taylor J Geddes; Maria Ochiai; Noah M Lampl; W Wade Kothmann; Sara R Fierstein; Victoria Kent; Kathleen DeCicco-Skinner
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

8.  Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib.

Authors:  John D Strickley; Aaron C Spalding; M Tye Haeberle; Timothy Brown; Don A Stevens; Jae Jung
Journal:  Exp Hematol Oncol       Date:  2018-08-28

9.  The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis.

Authors:  Christine Hoesl; Thomas Fröhlich; Jennifer E Hundt; Hermann Kneitz; Matthias Goebeler; Ronald Wolf; Marlon R Schneider; Maik Dahlhoff
Journal:  Mol Oncol       Date:  2019-10-21       Impact factor: 6.603

10.  Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.

Authors:  Kathrin Hedegger; Hana Algül; Marina Lesina; Andreas Blutke; Roland M Schmid; Marlon R Schneider; Maik Dahlhoff
Journal:  Mol Oncol       Date:  2020-05-18       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.